NeOnc Technologies executes sub-license for NEO100/NEO212 in MENA, milestone toward $50M Quazar deal

NEONC TECHNOLOGIES HOLDINGS, INC.

NeOnc executed sub-license agreement with its Abu Dhabi subsidiary NuroCure for NEO100 and NEO212, covering UAE, GCC, and MENA.
This is the second of five conditions to close a $50M strategic investment from Quazar Investment at $25 per share.
Proposed structure: 70% of proceeds for NeOnc common stock, 30% for clinical trials and infrastructure in MENA.
Remaining conditions to be satisfied within 120 days, including legal formation of NuroMENA/NuroCure and finalizing offering documents.
Management also highlighted recent Russell Microcap Index inclusion as part of its capital markets strategy.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.